Clinical Trial News and Research

RSS

Multiple sclerosis drug Tysabri could be back on the market later in the year

The drug Tysabri which was approved by the Food and Drug Administration (FDA) for the treatment of multiple sclerosis in November 2004, was taken off the market in late February, after two cases of progressive multifocal leukoencephalopathy, or PML, appeared in patients given the drug during clinical trials.

9 Jun 2005

Doctors and patients think differently about clinical trials

A survey of patients and physicians regarding clinical trials shows that doctors don't recognize the importance of side effects as a barrier for their patients in deciding about whether to undergo experimental therapy.

9 Jun 2005

Lorus Therapeutics receives patent allowance to protect novel anticancer drug

Lorus Therapeutics today announced that its wholly owned subsidiary, GeneSense Technologies Inc. (GeneSense), has received notice from the European Patent Office of its intention to grant GeneSense's application for a patent of its novel antisense drug, GTI-2501.

9 Jun 2005

Virulizin granted orphan drug status in Europe

Lorus Therapeutics has announced that the EMEA (European Medicines Agency) has given a positive opinion on Lorus' application for orphan drug status to Virulizin, the company's lead anticancer drug for the treatment of pancreatic cancer.

8 Jun 2005

Doctors study surgery to stop epileptic seizures

Melinda Hillyard of Winchester, Va., first had epileptic seizures when she was eight years old. The seizures went away for years, then returned after the birth of her first child. "I never knew when my world would turn upside down," she recalled.

6 Jun 2005

Gene therapy for arthritis is both feasible and safe

Gene therapy for arthritis and other non-terminal, debilitating conditions and diseases is both feasible and safe, report researchers who conducted the world's first such test on the approach in patients with advanced rheumatoid arthritis.

6 Jun 2005

Patients with advanced heart failure significantly improved after receiving stem cell therapy

The study showed, 30 days after receiving the stem cells by injection into their hearts, patients improved an average of 41 percent in their hearts' pumping efficiency and the distance they could walk nonstop increased by 72 percent in a standard test widely used to assess heart patients.

6 Jun 2005

Researchers successfully image delivery and gene expression of DNA nanoparticles into lungs of CF mice

Researchers at the American Society of Gene Therapy Meeting in St. Louis announced that by using imaging technologies, they are able to successfully trace the delivery of DNA nanoparticles and the extent of gene transfer in the lungs of cystic fibrosis (CF) animals.

6 Jun 2005

Discovery will lead to more effective treatments for pulmonary arterial hypertension

A University of Alberta research team has discovered important new information they hope will lead to more effective treatments for pulmonary arterial hypertension (PAH)--a deadly form of high blood pressure in the pulmonary arteries caused by uncontrolled cell growth.

5 Jun 2005

Vaccine targets tumors where they live

Vaccine strategies are being designed to battle cancer, but their use for metastatic melanoma is a challenge.

3 Jun 2005

Helix opens additional sites for its Topical Interferon Alpha-2b Phase II clinical study

Helix BioPharma announced today the opening of two additional German sites for the Phase II clinical trial of its Topical Interferon Alpha-2b product at the Charité Berlin, one of the largest university hospitals in Europe.

2 Jun 2005

Novel topical treatment of psoriasis

Cytochroma Inc. today announced results from a Phase Ia clinical study for CTA018, a novel vitamin D analog developed for the treatment of psoriasis.

2 Jun 2005

New shingles vaccine

Doctors say they have come up with a vaccine that can reduce both the incidence and the severity of shingles by more than half.

2 Jun 2005

Study suggests continuous NSAID treatment more effectively reduces X-Ray progression than intermittent treatment

A widely under-recognized form of arthritis, ankylosing spondylitis (AS) is a chronic, progressive disease targeting the spine.

2 Jun 2005

You can teach your child to eat healthier

Parents, take heart: You can teach your child to eat healthier. A study of preadolescent children found that those who attended a behaviorally oriented nutrition education program and were taught to follow a diet low in saturated fat and dietary cholesterol adopted significantly better dietary habits over several years compared to their peers who received only general nutritional information.

1 Jun 2005

Triple approach is promising against cancer cells

A trimodal treatment strategy combining chemotherapy, radiation therapy, and a protein kinase inhibitor is much more effective against cancer cells than any combination of only two treatment methods.

1 Jun 2005

Hybridon collaborates to develop immune modulatory (IMO) compounds for asthma and allergy

Hybridon today announced it had entered into research collaboration and license agreements with Novartis for the discovery, optimization, development and commercialization of Toll-like receptor 9 (TLR9) drug candidates targeting asthma and allergy based on Hybridon's proprietary immune modulatory oligonucleotide (IMO) technology platform.

1 Jun 2005

Steroid treatment for prematurity put to the test

Babies whose mothers received steroid injections before giving birth have no higher risk of heart disease at age 30 than those whose mothers received a placebo treatment.

30 May 2005

Bioniche Life Sciences granted European patent

Bioniche Life Sciences has announced that it has had another patent granted on its core technology: Mycobacterial Cell Wall-DNA Complex (MCC). The European Patent Organization (EPO) granted the patent: - "Composition and Method for Inducing Apoptosis in Prostate Cancer Cells" (EPO1165106)

30 May 2005

A new technique might allow women diagnosed with cancer the opportunity to have children when chemotherapy and radiation treatments rob them of their fertility

Freezing eggs is one thing; thawing them safely so they can lead to pregnancy is the challenge. In the past, efforts to freeze a woman's eggs, or oocytes, have not worked well because the cells are large. When the egg is thawed, ice crystals cause damage that prevents the egg from being fertilized.

29 May 2005

Clinical Trial News and Research

Multiple sclerosis drug Tysabri could be back on the market later in the year

Doctors and patients think differently about clinical trials

Lorus Therapeutics receives patent allowance to protect novel anticancer drug

Virulizin granted orphan drug status in Europe

Doctors study surgery to stop epileptic seizures

Gene therapy for arthritis is both feasible and safe

Patients with advanced heart failure significantly improved after receiving stem cell therapy

Researchers successfully image delivery and gene expression of DNA nanoparticles into lungs of CF mice

Discovery will lead to more effective treatments for pulmonary arterial hypertension

Vaccine targets tumors where they live

Helix opens additional sites for its Topical Interferon Alpha-2b Phase II clinical study

Novel topical treatment of psoriasis

New shingles vaccine

Study suggests continuous NSAID treatment more effectively reduces X-Ray progression than intermittent treatment

You can teach your child to eat healthier

Triple approach is promising against cancer cells

Hybridon collaborates to develop immune modulatory (IMO) compounds for asthma and allergy

Steroid treatment for prematurity put to the test

Bioniche Life Sciences granted European patent

A new technique might allow women diagnosed with cancer the opportunity to have children when chemotherapy and radiation treatments rob them of their fertility

eBook: Using iPSCs models for human disease research and drug discovery eBook

Latest eBooks

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Metabolomics

Improve fermentation and cell culture performance with real-time gas analysis

Scaling patient-derived organoid research

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer